Professional
Added to YB: 2026-03-18
Pitch date: 2026-01-23
MRK [neutral]
Merck & Co., Inc.
+8.28%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$285.4B
Pitch Price
$107.01
Price Target
N/A
Dividend
2.95%
EV/EBITDA
10.89
P/E
15.86
EV/Sales
4.94
Sector
Pharmaceuticals
Category
value
Artisan Value Fund Portfolio Holding: Merck & Co., Inc.
MRK (holding update): Health care co surged Nov on rotation to cheaper laggards. Market focused on Keytruda patent cliff 2028 & Gardasil headwinds, discounting late-stage pipeline despite dozens of programs & large opportunities. Strong balance sheet + robust FCF enable M&A & shareholder returns. Trading cheap vs pipeline potential.
Read full article (1 min)